Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics of pooled clinical trial patient population

From: Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Characteristic PsO studies PsA studies AS studies
Any secukinumab N = 5181 Any secukinumab N = 1380 Any secukinumab N = 794
Age (years), mean (SD) 45.7 (13.3) 48.8 (12.0) 42.4 (12.3)
Female, n (%) 1743 (33.6) 742 (53.8) 265 (33.4)
Caucasian, n (%) 4236 (81.8) 1212 (87.8) 612 (77.1)
BMI, mean (SD) 29.1 (6.6) 29.8 (6.3) 27.2 (5.5)
Relevant medical history or current medical condition, n (%)
 Hypertension 1089 (21.0) 551 (39.9) 176 (22.2)
 Hyperlipidemia 667 (12.9) 318 (23.0) 65 (8.2)
 Diabetes mellitus 341 (6.6) 171 (12.4) 22 (2.8)
 IBD 0 (0) 4 (0.3) 17 (2.1)
 Crohn’s disease 5 (0.1) 2 (0.1) 5 (0.6)
 Ulcerative colitis 10 (0.2) 2 (0.1) 3 (0.4)
 Uveitis 0 (0) 8 (0.6) 135 (17.0)
 Current smoker 1585 (30.6) 262 (19.0) 234 (29.5)
 Anti-TNF inadequate responder 784 (15.1) 435 (31.5) 227 (28.6)
  1. AS ankylosing spondylitis, BMI body mass index, IBD inflammatory bowel disease, N number of patients in the analysis, n number of patients with a response, PsA psoriatic arthritis, PsO psoriasis, SD standard deviation, TNF tumor necrosis factor